Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Features include: Neoplasia of the nasopharynx.
Biomarker and diagnostic research for nasopharyngeal carcinoma, susceptibility to, 2 has been reported in the published literature.
1 FDA-approved treatment is available for nasopharyngeal carcinoma, susceptibility to, 2, including PENPULIMAB (PENPULIMAB KCQX, approved 2025).
Brand Name | Generic Name | Mechanism | Approved | Market Status |
|---|---|---|---|---|
No clinical trials have been registered for nasopharyngeal carcinoma, susceptibility to, 2.
26 publications have been identified in PubMed for nasopharyngeal carcinoma, susceptibility to, 2. Research spans Epidemiology / Natural History (58%), Basic Science / Preclinical (23%), and Clinical Trial Publication (8%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 15 | 58% |
Data assembled from 5 of 12 sources · Last updated Sep 20, 2026, 5:37 PM UTC
Online Mendelian Inheritance in Man
PENPULIMAB KCQX
PENPULIMAB |
— |
2025 |
Available |
Gene therapy approaches for nasopharyngeal carcinoma, susceptibility to, 2 have been reported in the published literature.
View trials for nasopharyngeal carcinoma, susceptibility to, 2
Laboratory research |
6 |
23% |
Clinical study results | 2 | 8% |
Testing and diagnosis research | 1 | 4% |
Research summaries | 1 | 4% |
New treatment approaches | 1 | 4% |
Chan FC (2026). [PMID: 42203326](https://pubmed.ncbi.nlm.nih.gov/42203326/). *Anticancer Res*. [Epidemiology / Natural History]
Zhong L (2026). [PMID: 41589895](https://pubmed.ncbi.nlm.nih.gov/41589895/). *Journal of virology*. [Basic Science / Preclinical]
Zhang Y (2026). [PMID: 40908541](https://pubmed.ncbi.nlm.nih.gov/40908541/). *American journal of hypertension*. [Diagnostic / Biomarker]
Yang M (2026). [PMID: 41539347](https://pubmed.ncbi.nlm.nih.gov/41539347/). *European journal of pharmacology*. [Epidemiology / Natural History]
Bai S (2026). [PMID: 41416424](https://pubmed.ncbi.nlm.nih.gov/41416424/). *Oncology reports*. [Epidemiology / Natural History]
Li WJ (2026). [PMID: 41825161](https://pubmed.ncbi.nlm.nih.gov/41825161/). *Translational oncology*. [Clinical Trial Publication]
Liang Y (2025). [PMID: 39854120](https://pubmed.ncbi.nlm.nih.gov/39854120/). *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*. [Basic Science / Preclinical]
Hsu SW (2025). [PMID: 41006010](https://pubmed.ncbi.nlm.nih.gov/41006010/). *Anticancer research*. [Basic Science / Preclinical]
Bilal H (2025). [PMID: 40766085](https://pubmed.ncbi.nlm.nih.gov/40766085/). *Frontiers in microbiology*. [Epidemiology / Natural History]
Song S (2025). [PMID: 39235555](https://pubmed.ncbi.nlm.nih.gov/39235555/). *Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico*. [Epidemiology / Natural History]